Sanofi opens new R&D hub in Shanghai
This article was originally published in Scrip
Executive Summary
Sanofi is bucking a trend in China. While many foreign companies have slowed down their investment plans there because of the country's recent nationwide anti-corruption and anti-monopoly campaigns as well as increasingly tightening compliance policies that affected major multinationals including GlaxoSmithKline and Eli Lilly, Sanofi did exactly the opposite.